Your browser doesn't support javascript.
loading
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.
Chen, Hao; Lai, Mengzhen; Zhang, Tao; Chen, Yuqing; Tong, Linjiang; Zhu, Sujie; Zhou, Yang; Ren, Xiaomei; Ding, Jian; Xie, Hua; Lu, Xiaoyun; Ding, Ke.
Afiliação
  • Chen H; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy and the 1st Affiliated Hospital (Huaqiao Hospital), Jinan
  • Lai M; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, #555 Zuchongzhi Road, Shanghai 201203, China.
  • Zhang T; Department of Pharmacology, School of Pharmacy, Fudan University, #826 Zhangheng Road, Shanghai 201203, China.
  • Chen Y; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, #555 Zuchongzhi Road, Shanghai 201203, China.
  • Tong L; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy and the 1st Affiliated Hospital (Huaqiao Hospital), Jinan
  • Zhu S; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, #555 Zuchongzhi Road, Shanghai 201203, China.
  • Zhou Y; Institute for Translational Medicine, College of Medicine, Qingdao University, Qingdao 266021, China.
  • Ren X; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy and the 1st Affiliated Hospital (Huaqiao Hospital), Jinan
  • Ding J; State Key Laboratory of Bioorganic and Nature Product Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Road, Shanghai 200032, China.
  • Xie H; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, #555 Zuchongzhi Road, Shanghai 201203, China.
  • Lu X; University of Chinese Academy of Sciences, #19 Yuquan Road, Beijing 100049, China.
  • Ding K; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, #555 Zuchongzhi Road, Shanghai 201203, China.
J Med Chem ; 65(9): 6840-6858, 2022 05 12.
Article em En | MEDLINE | ID: mdl-35446588
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: J Med Chem Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: J Med Chem Ano de publicação: 2022 Tipo de documento: Article